PTK 2015 Banner 
2015 Peptalk M Banner 

 SHORT COURSE 4: GENOME EDITING USING CRISPR

Sunday, January 18 | 5:00-8:00 pm  

Mammalian cells are the workhorses for biopharmaceutical production. Thus, genome engineering/editing of these hosts to improve product quality and yields are of great interest. CRISPR, the newest gene editing tool, is gaining popularity among protein engineers and cell line developers. This course provides an introduction to CRISPR technology and insights on implementation for your protein expression and production pipeline.

Genome Editing in CHO Cells Using CRISPR Cas9 

Helene Faustrup Kildegaard, Ph.D., Co-Principal Investigator, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark 

Chinese hamster ovary (CHO) cells are widely used for the production of therapeutic proteins. Thus genome engineering of CHO cells for improved product quality and yield is of great interest. At this course, our hands-on experience with the CRISPR Cas9 technology for generating gene disruptions and targeted gene insertions in CHO cells will be presented together with the bioinformatics tool “CRISPy” for rapid sgRNA target selection.

Talk Title to be Announced

Norman Garceau, Ph.D., CSO, Blue Sky Biotech, Inc.

 

Additional Instructors to be Announced 

Speaker Biographies: 

Helene Faustrup KildegaardHelene Faustrup Kildegaard, Ph.D., Co-Principal Investigator, Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark 

Helene Faustrup Kildegaard is Co-Principal Investigator at the Novo Nordisk Foundation Center for Biosustainability at Technical University of Denmark. She received her Ph.D. degree in cellular and molecular biology from the Danish Cancer Society/Technical University of Denmark. She was then awarded a postdoc grant on therapeutic protein production in CHO from the Lundbeck Foundation and the Technical University of Denmark. Her current research focuses on applying  -omics data and developing efficient genome editing tools to engineer CHO cell factories for increased production and improved quality of therapeutic proteins.

Norman Garceau, Ph.D., CSO, Blue Sky Biotech, Inc.


<<Back to Short Courses